Mergers & Acquisitions ·
On July 21, 2026, Repligen Corporation entered into a definitive merger agreement to acquire BioLife Solutions, Inc.…
RGENRepligen Corp
On July 21, 2026, Repligen Corporation entered into a definitive merger agreement to acquire BioLife Solutions, Inc. for a total enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, totaling a value of $31.00 per share. The transaction is expected to close in the fourth quarter of 2026, subject to BioLife stockholder and regulatory approvals. Repligen expects the acquisition to be accretive to adjusted EPS by at least 5 cents in year one and 25 cents in year two, with anticipated synergies of $20 million in year one and $30 million in year two. Additionally, Repligen reported preliminary Q2 2026 revenue growth of approximately 12% reported and 13% organic. Repligen is a life sciences company that develops bioprocessing technologies for biological drug manufacturing.